EP Wealth Advisors LLC Has $1.29 Million Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

EP Wealth Advisors LLC decreased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 27.3% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,639 shares of the company’s stock after selling 992 shares during the quarter. EP Wealth Advisors LLC’s holdings in IDEXX Laboratories were worth $1,286,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Riverview Trust Co acquired a new position in IDEXX Laboratories in the first quarter valued at $26,000. Crewe Advisors LLC acquired a new position in shares of IDEXX Laboratories in the 1st quarter valued at about $26,000. Ridgewood Investments LLC bought a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at about $27,000. Institutional & Family Asset Management LLC acquired a new stake in IDEXX Laboratories during the second quarter worth approximately $28,000. Finally, nVerses Capital LLC bought a new stake in IDEXX Laboratories in the second quarter worth approximately $49,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Trading Down 1.9 %

IDXX opened at $495.42 on Wednesday. IDEXX Laboratories, Inc. has a fifty-two week low of $372.50 and a fifty-two week high of $583.39. The firm has a market capitalization of $40.92 billion, a PE ratio of 47.96, a P/E/G ratio of 4.32 and a beta of 1.33. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.37 and a quick ratio of 1.03. The company’s 50-day moving average is $487.24 and its 200 day moving average is $496.69.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $2.44 EPS for the quarter, missing the consensus estimate of $2.88 by ($0.44). The company had revenue of $1 billion during the quarter, compared to analysts’ expectations of $1.01 billion. IDEXX Laboratories had a return on equity of 57.03% and a net margin of 22.34%. The business’s revenue for the quarter was up 6.4% compared to the same quarter last year. During the same period last year, the company earned $2.67 earnings per share. As a group, research analysts predict that IDEXX Laboratories, Inc. will post 10.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

IDXX has been the topic of a number of research analyst reports. BTIG Research started coverage on IDEXX Laboratories in a report on Thursday, July 25th. They set a “buy” rating and a $580.00 price target on the stock. Piper Sandler dropped their price objective on shares of IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating on the stock in a report on Wednesday, August 14th. Stifel Nicolaus reduced their target price on IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a research note on Monday, June 24th. Finally, StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, July 10th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, IDEXX Laboratories currently has an average rating of “Moderate Buy” and an average price target of $582.25.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.